GSGustavo Pinheiro Santana

Gustavo Pinheiro Santana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gustavo Pinheiro Santana has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    De Novo Versus Upgrade Cardiac Resynchronization Therapy in Patients with Heart Failure: A Cohort Study

    by William Carvalho, Luíz Carlos Santana Passos, Tainá Teixeira Viana, Gustavo Pinheiro Santana, Jackson Pedro Barros-Pereira, Fernanda Pinheiro Martin Tapioca, Caio Rebouças Fonseca Cafezeiro

    Background: Cardiac resynchronization therapy (CRT) is beneficial for patients with heart failure (HF) who have left bundle branch block. However, the benefits of CRT in patients with prior cardiac stimulation remain uncertain. Objective: Compare short-term mortality between upgrade and de novo CRT implantation. Methods: This prospective cohort study included patients with HF indicated for CRT with left ventricular ejection fraction (LVEF) below 35%. Overall survival was assessed using the Kaplan–Meier method, and multivariate analysis was performed using a Cox [...] Abstract Background: Cardiac resynchronization therapy (CRT) is beneficial for patients with heart failure (HF) who have left bundle branch block. However, the benefits of CRT in patients with prior cardiac stimulation remain uncertain. Objective: Compare short-term mortality between upgrade and de novo CRT implantation. Methods: This prospective cohort study included patients with HF indicated for CRT with left ventricular ejection fraction (LVEF) below 35%. Overall survival was assessed using the Kaplan–Meier method, and multivariate analysis was performed using a Cox

  • Open Access

    Terapia de Ressincronização Cardíaca de Novo versus Upgrade em Pacientes com Insuficiência Cardíaca: Estudo de Coorte

    by William Carvalho, Luíz Carlos Santana Passos, Tainá Teixeira Viana, Gustavo Pinheiro Santana, Jackson Pedro Barros-Pereira, Fernanda Pinheiro Martin Tapioca, Caio Rebouças Fonseca Cafezeiro

    Fundamento: A terapia de ressincronização cardíaca (TRC) traz benefícios para pacientes com insuficiência cardíaca (IC) que apresentam bloqueio de ramo esquerdo. No entanto, os benefícios da TRC em pacientes com estimulação cardíaca prévia ainda são incertos. Objetivo: Comparar a mortalidade de curto prazo entre o upgrade e a implantação de TRC de novo. Métodos: Estudo de coorte prospectiva que incluiu pacientes com IC indicados para TRC com fração de ejeção do ventrículo esquerdo (FEVE) inferior a 35%. A sobrevida global foi avaliada pelo método de Kaplan-Meier, e a análise multivariada foi realizada utilizando o modelo de regressão de Cox. Resultados: Foram avaliados 412 pacientes com um acompanhamento médio de 59 ± 8 meses. Destes, 104 pacientes estiveram no grupo upgrade enquanto 308 pacientes foram incluídos grupo de novo. A doença de Chagas foi a causa mais prevalente de IC, com 148 casos (36%). Enquanto o grupo de novo cursou com aumento da FEVE (de 25% ± 6,7% para 28% ± 16,3%, p = 0,005), os pacientes que realizaram upgrade não apresentaram diferença estatística na FEVE aos 6 meses (de 27,5% ± 6,9% para 27,5% ± 15,5%, p = 0,6). A mortalidade global em 1 ano foi de 122 casos (29,6%). Em análise multivariada, apenas FEVE e upgrade de TRC permaneceram independentemente associadas ao desfecho (hazard ratio: 0,93, intervalo de confiança: 0,90 a 0,97, p = 0,001; hazard ratio: 2,90, intervalo de confiança: 1,21 a 7,10, p = 0,002, respectivamente). Conclusão: Nesta população de IC, o grupo upgrade foi associado à maior mortalidade em 1 ano quando comparado com o grupo de novo.

  • Open Access

    Impact of Tricuspid Repair on Surgical Death in Patients Undergoing Mitral Valve Surgery Due to Rheumatic Disease

    by Gustavo P. Santana, Rodrigo M. Vieira de Melo, Tainá T. Viana, Daniela N. Velame da Silva, Clara S. Figueiredo, Diogo F.C. de Azevedo, Osvaldemar R.N. Junior, Edmundo J.N. Câmara, Luanna M. Damasceno, Ana Luísa A.A. Silva, et al.


  • Open Access

    Upgrade is independently associated with short-term mortality after cardiac resynchronization therapy.

    by Tainá Viana, Gustavo Pinheiro Santana, William Carvalho, Luiz Carlos Santana Passos, Aline Grimaldi, Polliana Roriz, Thais Nascimento, Rodrigo Morel Vieira de Melo

    Title: Upgrade is independently associated with short-term mortality after cardiac resynchronization therapy.

  • Open Access

    Impact of Preoperative Pulmonary Hypertension on Early Surgical Death in Patients Undergoing Mitral Valve Surgery due to Rheumatic Diseas

    by Gustavo Pinheiro Santana, Rodrigo M Vieira De Melo, Tainá T Viana, Luanna M Damasceno, Pedro F Soares, José Vs Santos, Arthur Tolentino, Edmundo J.N Câmara, Luiz Cs Passos

    Objective: In a population of patients undergoing cardiac surgery for rheumatic mitral valve disease, evaluate the impact of preoperative PH on early surgical mortality. Methods: This is a prospective cohort carried out from January 1, 2017 to December 30, 2020. All patients over 18 years of age who underwent cardiac surgery to correct rheumatic mitral valve disease with functional tricuspid regurgitation in an echocardiogram performed up to 6 months before surgery were included. Systolic pulmonary artery pressure (sPAP) value was also defined by preoperative echocardiogram evaluation. The primary outcome was surgical mortality. Results: 144 patients were included. The mean age was 46.2 (±12.3) years with 107 (74.3%) female individuals, the median left ventricular ejection fraction was 61.0% (55 - 67) and sPAP was 55.0 mmHg (46 - 74), with 45 (31.3%) individuals with right ventricular dysfunction. The predominant valve disease was mitral stenosis (74.3%). The prevalence of severe tricuspid regurgitation was 47.2%. The total in-hospital mortality was 15 (10.4%) individuals. sPAP was independently associated with early surgical death RR 1.04 (1.01 – 1.07), p = 0.003. To determine a sPAP cut-off that indicates higher mortality and help decision making in clinical practice, we performed an analysis through the ROC curve (area 0.70, p=0.012). The estimated value of 73.5mmHg has the highest accuracy in our model for predicting early mortality. Conclusion: In patients with rheumatic heart disease who will undergo mitral valve surgery, pulmonary hypertension is associated with higher early mortality. Values above 73.5 mmHg predict higher risk and, in this part of the population, additional measures to control intraoperative and immediate postoperative pulmonary hypertension should be considered.

  • Open Access

    Indexing of left atrial volume by body surface area and height in a Brazilian population without previous heart disease and with a normal heart on echocardiography. Behavior in obese and overweight patients.

    by Edmundo J. N. Câmara, Flávia R. Valladares, Kin Key, Paloma Fonseca, Jun Kawaoka, Thais Campos, Marcus Santana, Alex Costa Cunha, Danilo Sousa Sampaio, Gustavo Pinheiro Santana, et al.

    Background: Left atrial (LA) volume indexing for body surface area (BSA) may underestimate LA size in obese and overweight people. Since LA volume is a risk marker for some cardiovascular events, it is suggested that indexing for height would be an alternative more apropriated method. The aims of this study were to find normal and the best cutoff values for LA volume indexed for height in our population. Methods: Echocardiograms from 2018 to 2021 were reviewed and patients without known cardiac disease and completely normal echocardiograms that had the left atrial volume (LAvol) measured by biplane Simpson’s method were included. LAvol was indexed by BSA (ml/m²), by height (LAvol/m), by height raised to exponent 2.7 (ml/ m2.7) and by height squared (ml/h²). Results: A total of 545 patients, 50.5 ± 13.4 y., 335 females (61,5%) were analyzed. There were 145 normal weight (26.6%), 215 overweight (39.4%), 154 obese (28.3%) and 31 low weight (5.7%) patients. To estabilish normal values we included only the normal weight group and considered normal values from 2SD below to 2SD above the mean. Mean and normal values were: LAvol/h 26.0 ±4.5, 17 – 30 ml/m, LAvol/ht² 16 ± 2.8, 10.4 - 21.6 ml/ ht² and LAvol/ht2.7 11.4 ± 2.2, 7.0 - 15.8 ml/m2.7. The normal LAvol/ht2.7 differed between male and female (11.4 ± 2.4 and 12.8 ± 2.6, p = 0.000). LA diameter, LAvol, LAvol/h, LAvol/h² and LAvol/ht2.7 increased progressively from low-weight, normal weight, overweight and obese patients (p= 0.0000), but not LAvol/BSA. When indexing LAvol for height, for height² and for height2.7 20.8%, 22.7% and 21.4% of the obese patients, respectively, were reclassified as enlarged LA, and 7.4%, 8.8% and 8.4% of the overweight patients as well. Using ROC curve analysis, LAvol/h² had the highest AUC ant the best predictive value to identify LA enlargement and LAvol/BSA the worst one. Conclusions: normal values for LAvol indexed for height by three different methods are described in normal individuals. We reinforce that LAvol indexation for BSA underestimates LA size in obese and overweight patients and in these groups, specially, indexing for height² is probably the best method to evaluate LAvol.